Multiple Myeloma Staging 

Updated: Sep 12, 2018
  • Author: Mohammad I Abu Zaid, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Sections

Classification for Multiple Myeloma

Staging for multiple myeloma does not use the TNM system. Instead, the following systems are commonly used to characterize the bulk and aggressiveness of the disease:

  • International Myeloma Working Group (IMWG) diagnostic criteria [1]  
  • International Staging System (ISS) [2]
  • Revised International Staging System(R-ISS) [3]

International Myeloma Working Group diagnostic criteria

The IMWG has established definitions of multiple myeloma and smoldering multiple myeloma. Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and one or more myeloma-defining events and biomarkers of malignancy.

A myeloma-defining event consists of evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically any of the following:

  • Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)
  • Renal insufficiency: creatinine clearance <  40 mL per min or serum creatinine > 177 μmol/L (> 2 mg/dL)
  • Anemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value <  100 g/L
  • Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT

Biomarkers of malignancy are as follows:

  • Clonal bone marrow plasma cell percentage ≥60%
  • Involved:uninvolved serum free light chain ratio ≥100
  • More than 1 focal lesion on MRI studies

To meet the definition of smoldering multiple myeloma, both of the following criteria must be met:

  • Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60%
  • Absence of myeloma-defining events or amyloidosis

International Staging System

ISS stages are as follows:

  • Stage I: Serum beta-2 microglobulin <  3.5 mg/L and serum albumin ≥3.5 g/dL
  • Stage II: Not stage I or stage III
  • Stage III: Serum beta-2 microglobulin ≥ 5.5 mg/L

Revised International Staging System

R-ISS stages are as follows:

  • Stage I: ISS stage I and  standard-risk chromosomal abnormalities by fluorescence in situ hybridization (FISH)(ie, no high-risk) and serum lactate dehydrogenase (LDH) level at or below the upper limit of normal
  • Stage II: Not R-ISS stage I or III
  • Stage III: ISS stage III and  either high-risk chromosomal abnormalities by FISH (ie, presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16)) or serum LDH level above the upper limit of normal